Targeted Oncology1mon
Balancing Treatment Intensity and Resistance Mechanisms in First-Line EGFR-mutated NSCLC: Amivantamab + Lazertinib vs Osimertinib Monotherapy
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting ...
National Institute for Health and Care Excellence1mon
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Canada1mon
Health Canada New Drug Authorizations: 2016 Highlights
Tagrisso O (osimertinib, osimertinib mesylate) AstraZeneca Canada Inc - Tagrisso is used for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M ...
Frontiers2y
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
Introduction: Despite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as ...